A new drug that breezed through clinical trials is proving ineffective in the general population. ( From Christiane Truelove and her weekly Pharma Blog review (original source: The Onion, 2006, cited by Steve Woodruff, on Impactivi)) The Food and Drug Administration today approved the sale of the drug PharmAmorin, a prescription tablet developed by Pfizer to treat chronic distrust of large prescription-drug manufacturers. Pfizer executives characterized the FDA's approval as a "godsend" for sufferers of independent-thinking-related mental-health disorders. "Many individuals today lack the deep, abiding affection for drug makers that is found in healthy people, such as myself," Pfizer CEO Hank McKinnell said. "These tragic disorders are reaching epidemic levels, and as a company dedicated to promoting the health, well-being, and long life of our company's public image, it was imperative that we did something to combat them." Although many psychotropic drugs impart a generalized feeling of well-being, PharmAmorin is the first to induce and focus intense feelings of affection externally, toward for-profit drug makers. Pfizer representatives say that, if taken regularly, PharmAmorin can increase affection for and trust in its developers by as much as 96.5 percent. "Out of a test group of 180, 172 study participants reported a dramatic rise in their passion for pharmaceutical companies," said Pfizer director of clinical research Suzanne Frost. "And 167 asked their doctors about a variety of prescription medications they had seen on TV." Frost said a small percentage of test subjects showed an interest in becoming lobbyists for one of the top five pharmaceutical companies, and several browsed eBay for drug-company apparel. PharmAmorin, available in 100-, 200-, and 400-mg tablets, is classified as a critical-thinking inhibitor, a family of drugs that holds great promise for the estimated 20 million Americans who suffer from Free-Thinking Disorder. Pfizer will also promote PharmAmorin in an aggressive, $34.6 million print and televised ad campaign. One TV ad, set to debut during next Sunday's 60 Minutes telecast, shows a woman relaxing in her living room and reading a newspaper headlined "Newest Drug Company Scandal Undermines Public Trust." The camera zooms into the tangled neural matter of her brain, revealing a sticky black substance and a purplish gas. The narrator says, "She may show no symptoms, but in her brain, irrational fear and dislike of global pharmaceutical manufacturers is overwhelming her very peace of mind." After a brief summary of PharmAmorin's benefits, the commercial concludes with the woman flying a kite across a sunny green meadow, the Pfizer headquarters gleaming in the background. PharmAmorin is the first drug of its kind, but Pfizer will soon face competition from rival pharmaceutical giant Bristol-Myers Squibb. The company is developing its own pro-pharmaceutical-company medication, Brismysquibicin, which will induce warm feelings not just for drug corporations in general, but solely for Bristol-Myers Squibb. "A PharmAmorin user could find himself gravitating toward the products of a GlaxoSmithKline or Eli Lilly," BMS spokesman Andrew Fike said. "This could seriously impede the patient's prescription-drug-market acceptance, or worse, Pfizer's profits in the long run." "Brismysquibicin will be cheaper to produce and therefore far more affordable to those on fixed incomes," Fike added. The news of an affordable skepticism-inhibitor was welcomed by New York physician Christine Blake-Mann, who runs a free clinic in Spanish Harlem. "A lot of my patients are very leery of the medical establishment," Blake-Mann said. "This will help them feel better about it, and save money at the same time." PharmAmorin's side effects include nausea, upset stomach, and ignoring the side effects of prescription drug medication.